Aldeyra Therapeutics, Inc. announced that Mary E. Taylor, MPH has joined the Company as its Senior Vice President, Regulatory Affairs, effective February 8, 2016. Ms. Taylor will report directly to Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. Mary Taylor most recently as Senior Vice President Regulatory Affairs and Quality at Civitas Therapeutics.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.43 USD | +5.54% | +0.29% | -2.99% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.99% | 19Cr | |
+16.75% | 12TCr | |
+20.17% | 12TCr | |
+21.22% | 2.66TCr | |
-23.11% | 1.99TCr | |
-17.47% | 1.63TCr | |
-45.95% | 1.55TCr | |
-18.29% | 1.55TCr | |
+59.41% | 1.48TCr | |
+3.29% | 1.37TCr |
- Stock Market
- Equities
- ALDX Stock
- News Aldeyra Therapeutics, Inc.
- Aldeyra Therapeutics Appoints Mary Taylor, MPH as Senior Vice President, Regulatory Affairs